CLCS (Cell Source) E10: $0.00 (As of Dec. 2024)


CLCS Cell Source Inc CLCS
35 GF Score
Price $0.75
View Full Analysis

What is Cell Source E10?

Cell Source CLCS -9.64% 35 E10 is $0.00 as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cell Source's adjusted earnings per share data for the three months ended in Dec. 2024 was $-0.010. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-25), Cell Source's current stock price is $0.75. Cell Source's E10 for the quarter that ended in Dec. 2024 was $0.00. Cell Source's Shiller PE Ratio of today is .


Cell Source  (OTCPK:CLCS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cell Source E10 Related Terms


Cell Source E10 Historical Data

* Premium members only.

The historical data trend for Cell Source's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source E10 Chart

Cell Source Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.17 -0.17 0.00

Cell Source Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -0.17 -0.17 -0.17 0.00

CLCS vs EDSA, CTXR, ASBP: E10 Comparison

For the Biotechnology subindustry, Cell Source's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell Source Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cell Source's Shiller PE Ratio falls into.


CLCS
35GF Score
Cell Source Inc CLCS
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cell Source's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.01/315.6050*315.6050
=-0.010

Current CPI (Dec. 2024) = 315.6050.

Cell Source Quarterly Data

per share eps CPI Adj_EPS
201503 -0.020 236.119 -0.027
201506 -0.020 238.638 -0.026
201509 -0.030 237.945 -0.040
201512 -0.030 236.525 -0.040
201603 -0.030 238.132 -0.040
201606 -0.030 241.018 -0.039
201609 -0.030 241.428 -0.039
201612 0.050 241.432 0.065
201703 -0.040 243.801 -0.052
201706 -0.030 244.955 -0.039
201709 -0.020 246.819 -0.026
201712 -0.020 246.524 -0.026
201803 -0.030 249.554 -0.038
201806 -0.020 251.989 -0.025
201809 -0.020 252.439 -0.025
201812 -0.020 251.233 -0.025
201903 -0.060 254.202 -0.074
201906 -0.040 256.143 -0.049
201909 -0.060 256.759 -0.074
201912 -0.020 256.974 -0.025
202003 -0.040 258.115 -0.049
202006 -0.050 257.797 -0.061
202009 -0.050 260.280 -0.061
202012 -0.060 260.474 -0.073
202103 -0.050 264.877 -0.060
202106 -0.050 271.696 -0.058
202109 -0.060 274.310 -0.069
202112 -0.030 278.802 -0.034
202203 -0.050 287.504 -0.055
202206 -0.040 296.311 -0.043
202209 -0.040 296.808 -0.043
202212 -0.040 296.797 -0.043
202303 -0.050 301.836 -0.052
202306 -0.040 305.109 -0.041
202309 -0.040 307.789 -0.041
202312 -0.030 306.746 -0.031
202403 -0.040 312.332 -0.040
202406 -0.040 314.175 -0.040
202409 -0.040 315.301 -0.040
202412 -0.010 315.605 -0.010

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.00 mean?
Cell Source (CLCS) has a E10 of $0.00 as of Dec. 2024. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cell Source and its competitors.
Is Cell Source's E10 too high?
Cell Source's current E10 is $0.00. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's E10 compare to EDSA and CTXR?
Cell Source's E10 of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cell Source and its competitors. Cell Source's current E10 is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current E10 of $0.00. The current E10 is $0.00. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Cell Source (CLCS), the current E10 is $0.00 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price